Research results on whether axitinib (Inlida) can be used in combination with chemotherapy drugs

Axitinib is an oral small molecule vascular endothelial growth factor receptor (VEGFR) inhibitor, mainly used to treat patients with advanced renal cell carcinoma (RCC). Its mechanism blocks tumor angiogenesis by inhibiting the VEGFR signaling pathway, thereby inhibiting tumor growth and metastasis. In clinical practice, researchers have also tried to combine axitinib with traditional chemotherapy drugs to evaluate its potential in enhancing anti-tumor efficacy.

Multiple clinical studies have shown that axitinib combined with certain chemotherapy drugs can improve disease control rates in specific patient groups. For example, in patients with advanced solid tumors, combination regimens can help enhance anti-tumor activity and improve partial response rate (PR) and progression-free survival (PFS), especially in patients who are resistant to or relapsed with single-agent therapy. Combination therapy achieves multi-target intervention by acting on angiogenesis and tumor cell proliferation simultaneously.

However, combined use also carries a higher risk of adverse effects. Studies have found that when axitinib is used simultaneously with chemotherapy drugs, patients may experience side effects such as increased blood pressure, hand-foot syndrome, proteinuria, and bone marrow suppression. Clinically, it is necessary to closely monitor blood pressure, liver and kidney function, and blood routine indicators, and adjust the dose or suspend treatment in a timely manner according to the patient's tolerance to balance efficacy and safety.

Overall, axitinib combined with chemotherapy drugs has shown certain clinical efficacy improvement potential, but indications and patient populations still need to be carefully selected. In the future, more multi-center, large-sample clinical trials will help clarify the optimal dosage regimen, treatment schedule and adverse reaction management of combined drugs, and provide more personalized treatment strategies for patients with advanced renal cell carcinoma and other solid tumors.

Reference materials:https://www.drugs.com/